Coegin Pharma AB (NGM: COEGIN)

Market Cap	90.66M
Revenue (ttm)	n/a
Net Income (ttm)	-28.08M
Shares Out	15.96M
EPS (ttm)	-2.89
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,671
Open	n/a
Previous Close	6.40
Day's Range	n/a
52-Week Range	2.58 - 8.30
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 22, 2024

About Coegin Pharma AB

Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascula...

• Industry: Pharmaceutical Preparations
• Founded: 2005
• Employees: 2
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: COEGIN